Restera

Restera operates in medical technology and digital health, with a clinical-stage focus on obstructive sleep apnea. Its proposed approach is a miniature neurostimulation implant placed using an ultrasound-guided needle procedure, targeting neural pathways that include the hypoglossal nerve and ansa cervicalis. This gives the company a distinct procedural emphasis: minimizing incision size and enabling outpatient placement. Its broader competitive context includes established non-invasive treatments such as CPAP and implantable nerve-stimulation approaches for sleep apnea. The available company information does not identify named competitors or provide comparative clinical outcomes, pricing, regulatory status, or adoption data, so a defensible ranking against individual companies is not possible. Restera’s reported seven clinical studies, 80 subjects, and 16 peer-reviewed publications suggest a clinical evidence-building effort, while its 1–10 employee range and single recorded investor indicate a much smaller disclosed operating footprint than established device manufacturers. Its differentiation currently rests on its proposed delivery method and stimulation targets; clinical efficacy, safety, and usability will determine how meaningful that distinction is in the market.

Restera was founded in 2021 and is described as an active, clinical-stage medical technology company based in Santa Clara. The main identifiable financing inflection point is in 2023. Structured company information lists one Seed round on Jan 1, 2023 and names Forepont Capital Partners as an investor; identity and financial signals instead describe a $25 million Series A in 2023. Because the round classification conflicts, the amount and stage should not be read as a fully reconciled financing history. The available employee band is 1–10, and no hiring news or workforce growth trend is documented. Product development is centered on a needle-delivered neurostimulation implant for obstructive sleep apnea, with ultrasound-guided placement and stimulation targets including the hypoglossal nerve and ansa cervicalis. Restera reports seven clinical studies, 80 subjects, and 16 peer-reviewed publications, indicating that clinical investigation is a key part of its development path. However, the information available does not establish the timing or outcomes of those studies, regulatory progress, a commercial product launch, or post-2023 funding. The trajectory is therefore best characterized as early-stage clinical development with limited evidence of publicly documented operational expansion.